PRA was awarded a rheumatoid arthritis study contract based on our strategy for achieving first-patient-in (FPI) by the end of the calendar year. PRA’s plan depended on a closely managed project with clear timelines and responsibilities, as well as selecting key sites that could support our goal. PRA reduced the project’s cost by approximately 15% through our ability to enroll the targeted number of patients with fewer sites and in a shorter time period.
Explore related content and topics

CRISPR Technology Offers New Hope for Patients with Devastating Diseases
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a powerful new gene-editing tool with unprecedented implications for the future…

Industry Watch
In this third week of January, we bring our readers research updates on antibiotic resistance, and how in comparison, resistance to vaccines is rare.…

Industry Watch
In the second week of August, we bring you news of an existing arthritis drug could help a third of diabetes patients, delaying the progress of the…